Detailed Information

Cited 0 time in webofscience Cited 0 time in scopus
Metadata Downloads

A Multi-Center, Prospective, Observational Study to Evaluate the Therapeutic Effectiveness and Safety of an Olmesartan/Amlodipine Plus Rosuvastatin Combination Treatment in Patients with Concomitant Hypertension and Dyslipidemia

Authors
Lee, Bong-KiKim, Byeong-KeukPark, Jae HyoungChung, Jong-WonPark, Chang GyuKim, Jin WonKim, Young DaePark, Woo-JungKim, Sang-HyunCha, Jae-KwanKim, Cheol HoRha, Seung-WoonHong, Young JoonShin, Mi-SeungCho, Seong WookSung, Young-HeeLee, KiheonYu, Jae-MyungRyu, Dong-RyeolYu, SungwookSong, Tae-JinKu, Bon DKim, Sin-GonPark, Hwan-CheolCho, Deok-KyuKim, Byung-SuHan, Seong-WooPark, Sung-JiPark, Gyung-MinHan, Kyoo-Rok
Issue Date
Jan-2025
Publisher
MDPI AG
Keywords
blood pressure; dyslipidemia; hypertension; low-density lipoprotein cholesterol; observational study; single-pill combination
Citation
Journal of Clinical Medicine, v.14, no.2, pp 1 - 15
Pages
15
Indexed
SCIE
SCOPUS
Journal Title
Journal of Clinical Medicine
Volume
14
Number
2
Start Page
1
End Page
15
URI
https://scholarworks.bwise.kr/hanyang/handle/2021.sw.hanyang/206580
DOI
10.3390/jcm14020308
ISSN
2077-0383
2077-0383
Abstract
Introduction: This study assessed the therapeutic effectiveness of a single-pill combination (SPC) of olmesartan/amlodipine plus rosuvastatin for blood pressure (BP) and low-density lipoprotein cholesterol (LDL-C) in patients with hypertension and dyslipidemia. Methods: Adult patients with hypertension and dyslipidemia who were decided to be treated with the study drug were eligible. The primary endpoint was the proportion of patients who achieved BP, LDL-C and both BP and LDL-C treatment goals at weeks 24–48. Secondary endpoints were assessed at weeks 24–48 and included changes in BP and LDL-C levels from baseline; the proportion of patients who achieved treatment goals who were initially classified as uncontrolled at baseline; changes and percent changes in lipid parameters; changes in both BP and LDL-C levels among patients who reached treatment goals who were followed for more than 24 weeks; and the overall safety profile. Results: A total of 5476 patients were enrolled, and 4411 patients comprised the effectiveness evaluation set. The proportions of patients who reached the treatment goals for BP, LDL-C levels, and both BP and LDL-C levels were 67.93% [95% confidence interval (CI) 66.52–69.32], 80.19% [95% CI 78.85–81.49], and 58.07% [95% CI 56.43–59.7], respectively. Secondary endpoints showed statistically significant changes. Overall, the treatment was well tolerated. Conclusions: The treatment of patients with hypertension and dyslipidemia with the olmesartan/amlodipine plus rosuvastatin SPC was associated with significant decreases in SBP/DBP and LDL-C levels, and a high proportion of patients achieved the BP and LDL-C treatment goals. The finding of this study is worthwhile in that this study evaluated the effectiveness and safety in a broad patient population representative of those seen in everyday clinical practice.
Files in This Item
There are no files associated with this item.
Appears in
Collections
서울 의과대학 > 서울 내과학교실 > 1. Journal Articles

qrcode

Items in ScholarWorks are protected by copyright, with all rights reserved, unless otherwise indicated.

Related Researcher

Researcher Park, Hwan Cheol photo

Park, Hwan Cheol
서울 의과대학 (DEPARTMENT OF INTERNAL MEDICINE)
Read more

Altmetrics

Total Views & Downloads

BROWSE